Biodexa Pharmaceuticals PLC Unsponsored ADR (NASDAQ:BDRX) Short Interest Update

Biodexa Pharmaceuticals PLC Unsponsored ADR (NASDAQ:BDRX) was the recipient of a large decline in short interest in the month of April. As of April 30th, there was short interest totaling 17,090 shares, a decline of 58.2% from the April 15th total of 40,924 shares. Based on an average trading volume of 38,481 shares, the short-interest ratio is presently 0.4 days. Currently, 0.9% of the company’s shares are sold short.

Hedge Funds Weigh In On Biodexa Pharmaceuticals

An institutional investor recently bought a new position in Biodexa Pharmaceuticals stock. Sabby Management LLC purchased a new position in shares of Biodexa Pharmaceuticals PLC Unsponsored ADR (NASDAQ:BDRX) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 190,658 shares of the company’s stock, valued at approximately $433,000. Biodexa Pharmaceuticals makes up about 0.6% of Sabby Management LLC’s investment portfolio, making the stock its 10th biggest holding. Sabby Management LLC owned 28.04% of Biodexa Pharmaceuticals at the end of the most recent reporting period. 17.51% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

BDRX has been the subject of a number of analyst reports. Weiss Ratings raised shares of Biodexa Pharmaceuticals from a “sell (e)” rating to a “sell (e+)” rating in a report on Wednesday. Wall Street Zen lowered shares of Biodexa Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Monday, March 30th. One research analyst has rated the stock with a Sell rating, According to MarketBeat, Biodexa Pharmaceuticals has an average rating of “Sell”.

Biodexa Pharmaceuticals Price Performance

BDRX traded down $0.10 during trading on Friday, reaching $3.30. 28,387 shares of the company’s stock were exchanged, compared to its average volume of 990,464. The company’s fifty day moving average price is $3.75 and its 200-day moving average price is $12.13. Biodexa Pharmaceuticals has a fifty-two week low of $2.86 and a fifty-two week high of $96.50.

Biodexa Pharmaceuticals (NASDAQ:BDRX) last announced its quarterly earnings results on Friday, March 27th. The company reported $3.52 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.01) by $3.53.

Biodexa Pharmaceuticals Company Profile

Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of Type 1 diabetes and rare/orphan cancers of the brain. Its lead product candidate Tolimidone, a selective activator of the lyn kinase enzyme, currently under Phase II studies for the treatment of Type 1 diabetes. The company is also developing MTX110, which is currently in Phase I studies for the treatment of diffuse intrinsic recurrent glioblastoma, diffuse midline glioma, and medulloblastoma; and MTD217, a program centered around a water-soluble drug formulation that can be easily infused or injected simultaneously, or sequentially, directly into the cancer microenvironment, currently under preclinical studies for the treatment of leptomeningeal disease.